- Kissei of Japan has licensed its novel diabetes drug KAD-1229 to Servier of France for development and commercialization in Europe. The drug is currently in Phase II testing in Japan, and is believed to act by blocking ATP-dependent potassium channels and stimulating insulin release from the pancreas. KAD-1229's short duration of action means that it will only be used for the management of post-prandial glucose levels, according to Pharma Japan. A licensing partner for the US market is being sought.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze